Annexon, Inc. Common Stock (ANNX) is a publicly traded Healthcare sector company. As of May 20, 2026, ANNX trades at $5.05 with a market cap of $812.66M and a P/E ratio of -3.71. ANNX moved +2.65% today. Year to date, ANNX is -3.45%; over the trailing twelve months it is +140.00%. Its 52-week range spans $1.29 to $7.85. Analyst consensus is strong buy with an average price target of $14.00. Rallies surfaces ANNX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Annexon Secures $225M Runway, Q4 2026 Topline Phase 3 Data Expected: Annexon ended Q1 2026 with $225 million in cash, cash equivalents and short-term investments, expecting funding into the second half of 2027. The company anticipates topline ARCHER II Phase 3 vonaprument data in Q4 2026, BLA submission for tanruprubart in 2026 and POC results for ANX1502.
| Metric | Value |
|---|---|
| Price | $5.05 |
| Market Cap | $812.66M |
| P/E Ratio | -3.71 |
| EPS | $-1.34 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.85 |
| 52-Week Low | $1.29 |
| Volume | 1.54M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-206.69M |
| Gross Margin | 0.00% |
8 analysts cover ANNX: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $14.00.